**Selected Publications**

1. Dai L#, Sheng B#**\***, Chen T#, Wu Q#, Liu R#, Cai C, Wu L, Yang D, Hamzah H, Liu Y, Wang X, Guan Z, Yu S, Li T, Tang Z, Ran A, Che H, Chen H, Zheng Y, Shu J, Huang S, Wu C, Lin S, Liu D, Li J, Wang Z, Meng Z, Shen J, Hou X, Deng C, Ruan L, Lu F, Chee M, Quek TC, Srinivasan R, Raman R, Sun X, Wang YX, Wu J, Jin H, Dai R, Shen D, Yang X, Guo M, Zhang C, Cheung CY, Tan GSW, Tham YC, Cheng CY, Li H#**\***, Wong TY**\***, **Jia W\***. A deep learning system for predicting time to progression of diabetic retinopathy. ***Nat Med.*** 2024, Jan 4. doi: 10.1038/s41591-023-02702-z.
2. Ni Y, Qian L, Siliceo SL, Long X, Nychas E, Liu Y, Ismaiah MJ, Leung H, Zhang L, Gao Q, Wu Q, Zhang Y, Jia X, Liu S, Yuan R, Zhou L, Wang X, Li Q, Zhao Y, El-Nezami H, Xu A, Xu G, Li H, Panagiotou G, **Jia W\***. Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. ***Cell Metab.*** 2023;35(9):1530-47.e8.
3. Chen S, Lu J, Peng D, Liu F, Lu W, Zhu W, Zhou J, **Jia W\***. Effect of a Mobile Health Technology-Based Diabetes Education Program on Glucose Control in Patients With Type 2 Diabetes Initiating Premixed Insulin: A Prospective, Multicenter, Observational Study. ***Diabetes Care***. 2023;46(1):e6-e7.
4. Zhang Y, Zhu Y, Wang J, Jin L, Guo M, Chen L, Zhang L, Li Y, Wan B, Zhang R, **Jia W\***, Hu C. Neuregulin4 Acts on Hypothalamic ErBb4 to Excite Oxytocin Neurons and Preserve Metabolic Homeostasis. ***Adv Sci (Weinh)***. 2023;10(16):e2204824.
5. Hou X, Wang L, Zhu D, Guo L, Weng J, Zhang M, Zhou Z, Zou D, Ji Q, Guo X, Wu Q, Chen S, Yu R, Chen H, Huang Z, Zhang X, Wu J, Wu J, **Jia W\***. Prevalence of diabetic retinopathy and vision-threatening diabetic retinopathy in adults with diabetes in China. ***Nat Commun***. 2023;14(1):4296.
6. Guan Z, Li H, Liu R, Cai C, Liu Y, Li J, Wang X, Huang S, Wu L, Liu D, Yu S, Wang Z, Shu J, Hou X, Yang X, **Jia W\***, Sheng B. Artificial intelligence in diabetes management: Advancements, opportunities, and challenges. ***Cell Rep Med***. 2023;4(10):101213.
7. Kuang J, Wang J, Li Y, Li M, Zhao M, Ge K, Zheng D, Cheung KCP, Liao B, Wang S, Chen T, Zhang Y, Wang C, Ji G, Chen P, Zhou H, Xie C, Zhao A, **Jia W\***, Zheng X, Jia W. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis. ***Cell Metab***. 2023;35(10):1752-66.e8.
8. Ye X, Yu R, Jiang F, Hou X, Wei L, Bao Y, **Jia W\***. Osteocalcin and Risks of Incident Diabetes and Diabetic Kidney Disease: A 4.6-Year Prospective Cohort Study. ***Diabetes Care***. 2022;45(4):830-6.
9. Li M, Wang S, Li Y, Zhao M, Kuang J, Liang D, Wang J, Wei M, Rajani C, Ma X, Tang Y, Ren Z, Chen T, Zhao A, Hu C, Shen C, Jia W, Liu P, Zheng X, **Jia W\***. Gut microbiota-bile acid crosstalk contributes to the rebound weight gain after calorie restriction in mice. ***Nat Commun***. 2022;13(1):2060.
10. Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, Pohl D, Hanhineva K, Liu Y, Xu A, Nielsen HB, Belda E, Clément K, Loomba R, Li H, **Jia W\***, Panagiotou G. Risk assessment with gut microbiome and metabolite markers in NAFLD development. ***Sci Transl Med***. 2022;14(648):eabk0855.
11. Cai C, Liu Y, Li Y, Shi Y, Zou H, Bao Y, Shen Y, Cui X, Fu C, **Jia W\***. Effectiveness of quality of care for patients with type 2 diabetes in China: findings from the Shanghai Integration Model (SIM). ***Front Med***, 2022, 16(1): 126-38.
12. Zhou J, Chen S, Cheng J, Zhu J, Lou Y, Bao Y, **Jia W\***. Ultra rapid lispro improves postprandial glucose control versus lispro in combination with insulin glargine/degludec in adults with type 2 diabetes: a prospective, randomized, double-blind, phase 3 trial. ***Sci Bull (Beijing)***. 2022;67(17):1785-91.
13. Zheng X, Chen T, Jiang R, Zhao A, Wu Q, Kuang J, Sun D, Ren Z, Li M, Zhao M, Wang S, Bao Y, Li H, Hu C, Dong B, Li D, Wu J, Xia J, Wang X, Lan K, Rajani C, Xie G, Lu A, Jia W, Jiang C, **Jia W\***. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism[J]. ***Cell Metab***, 2021, 33(4): 791-803.e7.
14. Xu B, Liu C, Zhang H, Zhang R, Tang M, Huang Y, Jin L, Xu L, Hu C, **Jia W\***. Skeletal muscle-targeted delivery of Fgf6 protects mice from diet-induced obesity and insulin resistance. ***JCI Insight***. 2021;6(19).
15. **Jia W\***, Zhang P, Zhu D, Duolikun N, Li H, Bao Y, Li X. Evaluation of an mHealth-enabled hierarchical diabetes management intervention in primary care in China (ROADMAP): A cluster randomized trial. ***PLoS Med***. 2021;18(9):e1003754.
16. **Jia W\***, Ma J, Miao H, Wang C, Wang X, Li Q, Lu W, Yang J, Zhang L, Yang J, Wang G, Zhang X, Zhang M, Sun L, Yu X, Du J, Shi B, Xiao C, Zhu D, Liu H, Zhong L, Xu C, Xu Q, Liang G, Zhang Y, Li G, Gu M, Liu J, Yuan G, Yan Z, Yan D, Ye S, Zhang F, Ning Z, Cao H, Pan D, Yao H, Lu X, Ji L. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS). ***Sci Bull (Beijing)***. 2021;66(15):1581-90.
17. Ji L, Song W, Fang H, Li W, Geng J, Wang Y, Guo L, Cai H, Yang T, Li H, Yang G, Li Q, Liu K, Li S, Liu Y, Shi F, Li X, Gao X, Tian H, Ji Q, Su Q, Zhou Z, Wang W, Zhou Z, Li X, Xu Y, Ning Z, Cao H, Pan D, Yao H, Lu X, **Jia W\***. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). ***Sci Bull (Beijing)***. 2021;66(15):1571-80.
18. Zheng X, Chen T, Zhao A, Ning Z, Kuang J, Wang S, You Y, Bao Y, Ma X, Yu H, Zhou J, Jiang M, Li M, Wang J, Ma X, Zhou S, Li Y, Ge K, Rajani C, Xie G, Hu C, Guo Y, Lu A, Jia W, **Jia W\***. Hyocholic acid species as novel biomarkers for metabolic disorders. ***Nat Commun***. 2021;12(1):1487.
19. Dai L, Wu L, Li H, Cai C, Wu Q, Kong H, Liu R, Wang X, Hou X, Liu Y, Long X, Wen Y, Lu L, Shen Y, Chen Y, Shen D, Yang X, Zou H, Sheng B, **Jia W\***. A deep learning system for detecting diabetic retinopathy across the disease spectrum. ***Nat Commun***. 2021;12(1):3242.
20. Zhang J, Ni Y, Qian L, Fang Q, Zheng T, Zhang M, Gao Q, Zhang Y, Ni J, Hou X, Bao Y, Kovatcheva-Datchary P, Xu A, Li H, Panagiotou G, **Jia W\***. Decreased Abundance of Akkermansia muciniphila Leads to the Impairment of Insulin Secretion and Glucose Homeostasis in Lean Type 2 Diabetes. ***Adv Sci (Weinh)***. 2021;8(16):e2100536.
21. Li S, Yu H, Zhang P, Tu Y, Xiao Y, Yang D, Bao Y, Han J, **Jia W\***. The Nonlinear Relationship Between Psoas Cross-sectional Area and BMI: A New Observation and Its Insights Into Diabetes Remission After Roux-en-Y Gastric Bypass. ***Diabetes Care***. 2021;44(12):2783-6.
22. Shen Y, Fan X, Zhang L, Wang Y, Li C, Lu J, Zha B, Wu Y, Chen X, Zhou J, **Jia W\***. Thresholds of Glycemia and the Outcomes of COVID-19 Complicated With Diabetes: A Retrospective Exploratory Study Using Continuous Glucose Monitoring. ***Diabetes Care***. 2021;44(4):976-82.
23. Di Chen , Xinjie Zhao, Zhigang Sui, Huan Niu , Luonan Chen, Cheng Hu , Qiuhui Xuan, Xuhong Hou, Rong Zhang, Lina Zhou, Yanli Li, Huiming Yuan, Yukui Zhang, Jiarui Wu, Lihua Zhang, Ren'an Wu, Hai-Long Piao\*, Guowang Xu\* , **Weiping Jia\***. A multi-Omics investigation of the molecular characteristics and classification of six metabolic syndrome relevant diseases. ***Theranostics***. 2020; 10(5):2029-2046.
24. Cheng Hu, **Weiping Jia\***. Therapeutic medications against diabetes: What we have and what we expect. ***Adv Drug Deliv Rev***. 2019; 139:3-15.
25. Yunqin Ma, Mingliang Zhang, Haoyong Yu, Junxi Lu, Kenneth K.Y. Cheng, Jian Zhou, Haibing Chen, Haibing Chen, **Weiping Jia\***. Activation of G0/G1 switch gene 2 by endoplasmic reticulum stress enhances hepatic steatosis. ***Metabolism***. 2019; 99:32-44.
26. Pan Gao, Liliang Li, Liu Yang, Dingkun Gui, Jiarong Zhang, Junfeng Han, Jiajia Wang, Niansong Wang, Junxi Lu, Suzhen Chen, Liping Hou, Honglin Sun, Liping Xie, Jian Zhou, Chao Peng, Yan Lu, Xuemei Peng, Cunchuan Wang, Ji Miao, Umut Ozcan, Yu Huang, **Weiping Jia\***, Junli Liu\*. Yin Yang 1 protein ameliorates diabetic nephropathy pathology through transcriptional repression of TGFβ1. ***Sci Transl Med***. 2019;11(510).
27. Lei Xu, Rui He, Xiaohan Hua, Jun Zhao, Jungong Zhao, Hui Zeng, Lianxi Li, Fang Liu, **Weiping Jia\***. The value of ankle-branchial index screening for cardiovascular disease in type 2 diabetes. ***Diabetes Metab Res Rev***. 2019; 35(1): e3076.
28. **Weiping Jia\***, Jianping Weng, Dalong Zhu, Linong Ji, Juming Lu, Zhiguang Zhou, et al. Standards of medical care for type 2 diabetes in China 2019. ***Diabetes Metab Res Rev***. 2019; 35(6): e3158.
29. Liping Ju, Junfeng Han, Xiaoyan Zhang, Yujie Deng, Han Yan, Congrong Wang, Xiaohua Li, Shuqin Chen, Miriayi Alimujiang, Xu Li, Qichen Fang, Ying Yang\*, **Weiping Jia\***. Obesity-associated inflammation triggers an autophagy-lysosomal response in adipocytes and causes degradation of perilipin 1. ***Cell Death & Disease***. 2019;10(2):121 .
30. Yun Shen, Wei Zhu, Lihua Lu, Fengdi Lu, Kai Kan, Yuqian Bao, Jian Zhou\*, **Weiping Jia\***. Contribution of structured self-monitoring of blood glucose to self-efficacy in poorly controlled diabetes patients in China. ***Diabetes Metab Res Rev***. 2019; 35(1): e3067.
31. Cheng Hu, **Weiping Jia\***. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. ***Diabetes***. 2018;67:3-11.
32. Shuqi Zhang, Keyue Ma, Alexandra A Schonnesen, Mingliang Zhang, Chenfeng He, Eric Sun, Chad M Williams, **Weiping Jia\***, Ning Jiang\*. High-throughput determination of the antigen specificities of T cell receptors in single cells. ***Nature Biotechnology***.2018; 36: 1156-1159.
33. Ling Dai,Ruogu Fang, Huating Li, Xuhong Hou, Bin Sheng\*, Qiang Wu\*, **Weiping Jia\***. Clinical report guided retinal microaneurysm detection with multi-sieving deep learning. ***IEEE Trans Med Imaging***. 2018;37(5):1149-1161.
34. Huating Li, Guangyu Wu, Qichen Fang, Mingliang Zhang, Xiaoyan Hui, Bin Sheng, Liang Wu,Yuqian Bao, Peng Li, Aimin Xu\*, **Weiping Jia\***. Fibroblast growth factor 21 increases insulin sensitivity through speciﬁc expansion of subcutaneous fat. ***Nat Commun***. 2018;9:272.
35. Jingyi Lu, Xiaojing Ma, Jian Zhou\*, Lei Zhang, Yifei Mo, Lingwen Ying, Wei Lu, Wei Zhu, Yuqian Bao, Vigersky RA, **Jia W\***. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. ***Diabetes Care***.2018; 41(11): 2370-2376.
36. **Jia W\***. China-leading the way in diabetes research. ***Lancet Diabetes Endocrinol***. 2016;4:S1.
37. Ying Liu, Kacey J Prentice, Judith A Eversley, Cheng Hu, Battsetseg Batchuluun, Katherine Leavey, Jakob B Hansen, David W Wei, Brian Cox, Feihan F Dai, **Jia W\***, Michael B Wheeler. Rapid Elevation in CMPF May Act As a Tipping Point in Diabetes Development. ***Cell Rep***. 2016 Mar 29;14(12):2889-900.
38. Hou X, Chen P, Hu G, Chen Y, Chen S, Ma X, Chen L, Yang Z, Yang W, **Jia W\***. Cardiometabolic disease is prevalent in normal-weight chinese adults. ***Journal of The American College of Cardiology***, 2016; 68(14):1599-1600.
39. Yin B, Li H, Sheng B\*, Hou X, Chen Y, Wu W, Li P, Shen R, Bao Y, **Jia W\***. Vessel extraction from non-fluorescein fundus images using orientation-aware detector. ***Medical Image Analysis***, 2015; 26(1): 232-242.
40. **Jia W\***, Xiao X, Ji Q, Ahn KJ, Chuang LM, Bao Y, Pang C, Chen L, Gao F, Tu Y, Li P, Yang J. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial, ***Lancet Diabetes Endocrinol***, 2015, 3(4): 254-62.
41. **Jia W\***, Tong N. Diabetes prevention and continuing health-care reform in China. ***Lancet Diabetes & Endocrinology***, 2015; 3(11):840-842.
42. Ma R C, Lin X, **Jia W\***. Causes of type 2 diabetes in China. ***Lancet Diabetes Endocrinol***, 2014, 2(12): 980-91.
43. **Jia W\***. Diabetes: a challenge for China in the 21st century. ***Lancet Diabetes Endocrinol***, 2014, 2(4): e6-7.
44. Li H, Dong K, Fang Q, Hou X, Zhou M, Bao Y, Xiang K, Xu A, **Jia W\***. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: A 3-year prospective study in China. ***J Hepatol***, 2013, 58(3):557-63.
45. Fang Q, Li H, Song Q, Yang W, Hou X, Ma X, Lu J, Xu A, **Jia W\***. Serum Fibroblast Growth Factor 19 Levels Are Decreased in Chinese Subjects With Impaired Fasting Glucose and Inversely Associated With Fasting Plasma Glucose Levels. ***Diabetes Care***, 2013,36(9):2810-4.
46. He R, Shen J, Zhao J, Zeng H, Li L, Zhao J, Liu F\*, **Jia W\***. High cystatin C levels predict severe retinopathy in type 2 diabetes patients. ***Eur J Epidemiol***, 2013,28(9):775-8.
47. Li MH, Chen SW, Li YD, Chen YC, Cheng YS, Hu DJ, Tan HQ, Wu Q, Wang W, Sun ZK, Wei XE, Zhang JY, Qiao RH, Zong WH, Zhang Y, Lou W, Chen ZY, Zhu Y, Peng DR, Ding SX, Xu XF, Hou XH, **Jia W\***. Prevalence of unruptured cerebral aneurysms in Chinese adults aged 35 to 75 years: a cross-sectional study. ***Ann Intern Med***, 2013, 159(8):514-21.
48. Chen H, Lu J, Chen X, Yu H, Zhang L, Bao Y, Lu F, Tang J, Gu C, **Jia W\***. Low serum levels of the innate immune component ficolin-3 is associated with insulin resistance and predicts the development of type 2 diabetes. ***J Mol Cell Biol,*** 2012, 4(4):256–257.
49. Yu W, Ma RC, Hu C, So WY, Zhang R, Wang C, Tam CH, Ho JS, Lu J, Jiang F, Tang S, Ng MC, Bao Y, Xiang K, **Jia W\***, Chan JC. Association between KCNQ1 genetic variants and obesity in Chinese patients with type 2 diabetes. ***Diabetologia,*** 2012, 55(10): 2655-2659.
50. Lu J, Zhou J, Bao Y, Chen T, Zhang Y, Zhao A, Qiu Y, Xie G, Wang C, Jia W, **Jia W\***. Serum metabolic signatures of fulminant type 1 diabetes. ***J Proteome Res,*** 2012, 11(9): 4705−4711.
51. Li H, Gao Z, Zhang J, Ye X, Xu A, Ye J, **Jia W\***. Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. ***Diabetes***, 2012, 61(4): 797-806.
52. Yu W, Hu C, Zhang R, Wang C, Qin W, Lu J, Jiang F, Tang S, Bao Y, Xiang K, **Jia W\***. Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. ***Clin PharmacolTher,*** 2011, 89: 437-442.
53. Yu H, Xia F, Karen S.L. Lam, Wang Y, Bao Y, Zhang J, Gu Y, Zhou P, Lu J, **Jia W\***, Xu A. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. ***ClinChem***, 2011, 57(5): 691-700.
54. Hu C, Zhang R, Yu W, Wang J, Wang C, Pang C, Ma X, Bao Y, Xiang K, **Jia W\***. CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetic patients. ***Diabetes***, 2011, 60(11): 3085-3089.
55. Hu C, Wang C, Zhang R, Ng MC, Bao Y, Wang C, So WY, Ma RC, Ma X, Chan JC, Xiang K, **Jia W\***. Association of genetic variants of NOS1AP with type 2 diabetes in a Chinese population. ***Diabetologia***, 2010, 53: 290–298.
56. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, **Jia W\***. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. ***J Hepatol***, 2010, 53: 934-940.
57. Bao Y, Ma X, Li H, Zhou M, Hu C, Wu H, Tang J, Hou X, Xiang K, **Jia W\***. Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. ***BMJ***, 2010, 340: c2249.
58. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, **Jia W\***. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. ***J Clin Endocrinol Metab***, 2009, 94(6): 2151-2156.
59. Hu C, Wang C, Zhang R, Ma X, Wang J, Lu J, Qin W, Bao Y, Xiang K, **Jia W\***. Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. ***Diabetologia***, 2009, 52(7): 1322-1325.
60. Hu C, Zhang R, Wang C, Ma X, Wang C, Fang Q, Bao Y, Xiang K, **Jia W\***. A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. ***Diabetologia***, 2009, 52(3): 451-456.
61. Wang C, Hu C, Zhang R, Bao Y, Ma X, Lu J, Qin W, Shao X, Lu J, Xu J, Lu H, Xiang K, **Jia W\***. Common variants of hepatocyte nuclear factor 1beta are associated with type 2 diabetes in a Chinese population. ***Diabetes***, 2009, 58(4): 1023-7.
62. Wang C, Hou X, Bao Y, Pan J, Zuo Y, Zhong W, **Jia W\***, Xiang K. The metabolic syndrome increased risk of cardiovascular events in Chinese--a community based study. ***Int J Cardiol***, 2010, 139(2): 159-165.
63. Bao Y, Zhao T, Wang X, Qiu Y, Su M, **Jia W\***, Jia W. Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. ***J Proteome Res***, 2009, 8:1623-1630.
64. Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, Li Y, Gao X, Luan X, Wang W, **Jia W\***. Reference values for continuous glucose monitoring in Chinese subjects. ***Diabetes Care***, 2009, 32(7): 1188-1193.
65. **Jia W\***, Wu H, Bao Y, Wang C, Lu J, Zhu J and Xiang K. Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. ***J Clin Endocrinol Metab,*** 2007, 92(8): 3224-3229.
66. **Jia W\***, Pan C, Chen L, Bao Y, Lu J, Lu H, Tang J, Wu Y, Zuo Y, Jiang S, Xiang K. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. ***Diabetologia,*** 2007, 50: 286-292.
67. **Jia W\***, Xiang K, Chen L, Lu J, Wu Y. Epidemiological study on obesity and its comorbidities in urban Chinese older than 20 years of age in Shanghai, China. ***Obes Rev,*** 2002, 3: 157-165.
68. **Jia Weiping\***. “Continuous Glucose Monitoring”. ***Springer Nature Singapore Pte Ltd.***